Compare Eli Lilly And Co (LLY) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Value Index Fund ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Vanguard Value Index Fund ETF trades at $220.59 (market cap $262.40B). The key difference: Eli Lilly And Co is far larger — about 4× Vanguard Value Index Fund ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| LLY | VTV | |
|---|---|---|
Market Cap | $1.04T | $262.40B |
Volume | 3,064,878 | 3,293,281 |
Sector | Health | — |
52-Week High | $1.28K | $227.51 |
52-Week Low | $799.57 | $182.86 |
Typical Hold Time | 93 Days | 142 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Vanguard Value ETF (VTV) trades at $219.63, up 0.65% today, with a bearish technical signal but bullish moving averages. The fund offers a 2.3% dividend yield and has attracted institutional buying, including recent positions from QRG Capital Management and Blue Edge Capital. Value stocks have outperformed growth in 2026, with VTV leading among large-cap value ETFs due to its low 0.03% expense ratio and diversification away from tech mega-caps.
VTV presents a defensive opportunity amid market rotation from growth to value, supported by income appeal and lower volatility. Risks include prolonged underperformance versus the S&P 500 over the past decade and sensitivity to interest rate changes. The fund's reliance on traditional value sectors may lag if growth stocks rebound.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
